NVIDIA introduced Clara AI, a toolkit that includes 13 classification and segmentation artificial intelligence (AI) segmentation algorithms, and software tools built for radiologists.

Hologic Inc. opened its first Learning and Experience Centre in Zaventem, Belgium. The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) region, centralizing the education experience for Hologic’s technologies.

Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will respond to chemotherapy, according to a new study published in the journal Radiology: Artificial Intelligence.

Fonar Corp. reported publication of a chapter where the physician-author-researchers utilized the Fonar Upright Multi-Position MRI (magnetic resonance imaging) system. The title of their chapter is: Craniocervical Junction Syndrome: Anatomy of the Craniocervical and Atlantoaxial Junctions and the Effect of Misalignment on Cerebrospinal Fluid Flow.

Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient using the combination of the treatment planning system (TPS) RayStation from RaySearch in combination with the Mevion S250i Proton Therapy System with Hyperscan Pencil Beam Scanning.

Biologic age, a DNA-based estimate of a person’s age, is associated with future development of breast cancer, according to scientists at the National Institutes of Health. Biologic age was determined by measuring DNA methylation, a chemical modification to DNA that is part of the normal aging process. The study showed for every five years a woman’s biologic age was older than her chronologic or actual age, known as age acceleration, she had a 15 percent increase in her chance of developing breast cancer. The study was published online Feb. 22 in the Journal of the National Cancer Institute.

Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables efficient identification of which patients, despite symptoms suggestive of coronary artery disease (CAD), have a low risk of adverse cardiovascular events and can safely avoid invasive testing out to one year. These results from the ADVANCE trial were presented as a late-breaking trial during the American College of Cardiology’s (ACC) 68th Annual Scientific Session, March 16-18 in New Orleans, and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Imaging.